中国动脉硬化杂志2011，Vol.19Issue(12)：1011-1014,4.
过氧化体增殖物激活型受体α/γ激动剂对代谢综合征患者高敏C反应蛋白和基质金属蛋白酶9的影响
The Effect of Peroxisome Proliferator Activated Receptor-α/γ Agonist Intervention on Serum Concentration of High Sensitive C-reactive Protein and Matrix Metalloproteinase-9 in Patients with Metabolic Syndrome
柴湘平 1周胜华 1罗玉梅2
作者信息
- 1. 中南大学湘雅二医院,湖南省长沙市410011
- 2. 广东省深圳市龙岗区人民医院,广东省深圳市518172
- 折叠
摘要
Abstract
Aim To explore the effect of peroxisome proliferator activated receptors-α/γ (PPAR-α/γ) agonist intervention alone or in combination on serum concentration of high sensitive C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) in patients with metabolic syndrome. Methods 256 patients with metabolic syndrom were randomly assigned into basic treatment group, fenofibrate group, pioglitazone group, and fenofibrate + pioglitazone group. All patients received lifestyle interventions and medications to control blood pressure. Additionally, patients in the B group received placebo. Patients in the fenofibrate group received fenofibrate 0. 2 g once a day at night. Patients in the pioglitazone group received pioglitazone 15 mg once a day. Patients in the fenofibrate + pioglitazone group received both fenofibrate and pioglitazone as described above. The intervention lasted for 24 weeks. All patients' serum concentration of hs-CRP and MMP-9 were checked pre and post intervention.ResultsPatients' serum concentration of hs-CRP preand post intervention in each group were 6. 32 ± 1. 65 mg/L and 3. 52 ± 1. 98 mg/L in the fenofibrate group, 5. 85 ± 1. 59 mg/L and 3. 33 ± 1. 16 mg/L in the pioglitazone group, and 6. 49 ± 1. 34 mg/L and 2. 47 ±0. 91 mg/L in the fenofibrate + pioglitazone group respectively. Patients' serum concentration of MMP-9 pre and post intervention in each group were 179. 3 ±54. 9μg/L and 144. 9 ±30. 8μg/L in the fenofibrate group, 188. 7 ±62. 4μg/L and 146. 9 ± 27. 8 μg/L in the pioglitazone group, and 177. 5 ±58. 7 μg/L and 128. 8 ±34. 8 μg/L in the fenofibrate + pioglitazone group respectively. Conclusions Fenofibrate or pioglitazone intervention alone can reduce serum concentration of hs-CRP and MMP-9 in patients with metabolic syndrome. A combined use of fenofibrate and pioglitazone was more effective than single intervention with fenofibrate or pioglitazone.关键词
代谢综合征/过氧化体增殖物激活型受体α/γ激动剂/高敏C反应蛋白/基质金属蛋白酶9Key words
Metabolic Syndrome/Peroxisome Proliferator Activated Receptors-α/γ Agonists/High Sensitive Creactive Protein/Matrix Metalloproteinase-9分类
医药卫生引用本文复制引用
柴湘平,周胜华,罗玉梅..过氧化体增殖物激活型受体α/γ激动剂对代谢综合征患者高敏C反应蛋白和基质金属蛋白酶9的影响[J].中国动脉硬化杂志,2011,19(12):1011-1014,4.
